Athersys und Pfizer ....

Thema bewerten
Beiträge: 15
Zugriffe: 12.856 / Heute: 1
Athersys -   $ +0,00% Perf. seit Threadbeginn:   -100,00%
 
Chalifmann3:

Athersys und Pfizer ....

 
18.12.11 07:19
Hi biotechfreaks 1

Stammzellen,made by Athersys könnte sich auszahlen,denn ....

..... In a move that went unnoticed by investors, Athersys, Inc. (ATHX), a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life, reacquired all the rights to its Multi-Stem Cardiovascular Cell Therapy Program from its collaborator and partner, Angiotech Pharmaceuticals, Inc. In an example of one man’s pain is another man’s gain, the recent bankruptcy restructuring of Angiotech apparently drained its resources and lead to its inability and/or unwillingness to move forward with the promising program.

I first discussed Athersys in depth in a Seeking Alpha article on May 1, 2011. At the time, the stock was trading at about $2.80. As the stem cell sector has gone out of favor in the ensuing months, Athersys hasn’t been an exception and now trades at just $1.30 per share. Yet, it continues to make progress in the development of its Multi-Stem product, an off-the-shelf stem cell therapy that can be mass produced in a much greater multiple than the technology of the current sector leader (based on its $2,000,000,000 market cap), Australian based Mesoblast Ltd (MEOBF.PK). For those unfamiliar with the technologies of Athersys and Mesoblast, their cell technologies are similar in that they are both based on adult derived stem cells as opposed to the more controversial, embryonic stem cells. Recently, Geron Corporation (GERN), the leader in embryonic stem cell therapy, waved the white flag on its once promising, embryonic stem cell business.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Athersys und Pfizer .... 468800
>3x bewertet

Werbung

Entdecke die beliebtesten ETFs von Amundi

Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Russell 1000 Growth UCITS ETF - Acc
Perf. 12M: +38,69%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +32,46%
Amundi DJ Global Titans 50 UCITS ETF - Dist
Perf. 12M: +31,27%
Amundi MSCI World II UCITS ETF - USD Hedged Dist
Perf. 12M: +29,06%

 
25.01.12 06:58
CLEVELAND, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News) announced today that it has been granted U.S. patent 8,075,881 that covers the use of non-embryonic multipotent stem cells for the treatment of cardiovascular conditions including myocardial infarction, or heart attack, congestive heart failure, myocardial ischemia and other heart conditions. The patent also provides protection for multiple techniques for delivering the stem cells to treat the conditions. Athersys also announced the issuance in 2011 of more than 25 patents in the U.S. and other countries covering non-embryonic multipotent stem cells, their production, and usage.

The issued patents cover Athersys' proprietary MultiStem(R) product platform, which is an investigational stem cell therapy that has demonstrated therapeutic potential to treat a broad range of indications in the cardiovascular, neurological, and inflammatory and immune condition disease areas. Athersys currently has four clinical stage programs in acute myocardial infarction, ulcerative colitis, hematopoietic stem cell transplant support and ischemic stroke using its MultiStem product candidate.

"Cardiovascular disease represents an important opportunity area for MultiStem therapy, and the '881 patent provides the company with additional protection for its product candidates in this high value area," said William (B.J.) Lehmann, President and COO of Athersys. "Additionally, this and the other patents granted over the past year further expand and strengthen our stem cell intellectual property (IP) estate."

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
 
01.02.12 16:15
CLEVELAND, Ohio, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News), a leader in the emerging field of regenerative medicine, announced today grant funding aggregating $3.6 million to further advance its MultiStem(R) product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) to develop MultiStem for the treatment of traumatic brain injury (TBI). In addition, Athersys' subsidiary based in Belgium, ReGenesys BVBA, was awarded a $1.2 million (EURO0.9 million) grant from the Belgium's Agency for Innovation by Science and Technology (IWT) to further develop cell therapy formulations and manufacturing capabilities. The company has also been awarded funding recently to work in other areas, such as using MultiStem to treat chronic cardiovascular disease.

"These grant awards provide us with additional funding to support further development of MultiStem in specific therapeutic areas, as well as enhance our manufacturing platform," said Dr. Gil Van Bokkelen, Athersys Chairman & CEO. "Historically, we have been very successful at obtaining this type of funding, which reflects our commitment to outstanding science and technology development, and development of innovative new therapies."

NINDS TBI Grant

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Chalifmann3:

clinical results

 
01.02.12 22:48
CLEVELAND, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News) today announced positive results from its Phase I clinical trial of MultiStem(R), its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants (HSCT) for the treatment of leukemia and related conditions. According to the Center for International Blood and Marrow Transplant Research, there are approximately 25,000 allogeneic HSCT performed annually, globally. The study demonstrated that MultiStem therapy was well tolerated in both the single infusion and repeat infusion arms and also suggested that the therapy may provide benefit to recipients of allogeneic HSCT, such as reducing the incidence and severity of Graft-versus-Host Disease (GvHD) as compared to historical clinical experience. The results are consistent with previous preclinical studies that show that MultiStem provides multiple benefits in HSCT and other transplant models, such as reducing inflammatory damage and promoting graft acceptance.

These clinical results could provide the foundation for further, accelerated development of MultiStem to prevent or reduce the severity of GvHD, a potentially life-threatening complication of such transplants. Athersys received orphan drug designation from the U. S. Food and Drug Administration for prevention of GvHD in September 2010. Orphan drug designation, which is intended to facilitate drug development, provides substantial potential benefits to the sponsor, including funding for certain clinical studies, study-design assistance, tax incentives and seven years of market exclusivity for the product upon regulatory approval.

Data highlights from the study include:

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Chalifmann3:

stroke-news

 
06.02.12 15:42
CLEVELAND and NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) Medical School presented new research results this morning at the American Heart Association International Stroke Conference that highlight the role of the spleen in the mechanisms underlying how MultiStem(R), a novel allogenic stem cell therapy being developed by Athersys, Inc. (Nasdaq:ATHX - News), reduces damage and enhances functional recovery in animals after an ischemic stroke.

The study illustrated the potential benefits of MultiStem therapy for treating stroke using standard preclinical models. Researchers observed that intravenous administration of MultiStem one day after a stroke resulted in a substantial reduction in brain tissue loss 28 days post-stroke. The spleen is believed to play a significant role in the body's immune response to the stroke that can result in additional damage following the primary ischemic event. After administration, MultiStem cells limit the inflammatory cascade that results from the initial stroke, thereby reducing the secondary damage that occurs.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
 
15.06.12 23:30
Dieses Video wird aufgrund Ihrer Datenschutzeinstellungen nicht abgespielt. Wenn Sie dieses Video betrachten möchten, geben Sie bitte hier die Einwilligung, dass wir Ihnen Youtube-Videos anzeigen dürfen.
Bewerten
 
15.06.12 23:39
Dieses Video wird aufgrund Ihrer Datenschutzeinstellungen nicht abgespielt. Wenn Sie dieses Video betrachten möchten, geben Sie bitte hier die Einwilligung, dass wir Ihnen Youtube-Videos anzeigen dürfen.
Bewerten
 
16.06.12 00:02
Dieses Video wird aufgrund Ihrer Datenschutzeinstellungen nicht abgespielt. Wenn Sie dieses Video betrachten möchten, geben Sie bitte hier die Einwilligung, dass wir Ihnen Youtube-Videos anzeigen dürfen.
Bewerten
Anzeige: Der Uran-Megatrend 2025

Aktie mit Knalleffekt: Uran-Geheimtipp zündet das nächste Bohr-Update
 
28.06.12 11:30
Dieses Video wird aufgrund Ihrer Datenschutzeinstellungen nicht abgespielt. Wenn Sie dieses Video betrachten möchten, geben Sie bitte hier die Einwilligung, dass wir Ihnen Youtube-Videos anzeigen dürfen.
Bewerten
>1x bewertet
 
28.06.12 23:16
Dieses Video wird aufgrund Ihrer Datenschutzeinstellungen nicht abgespielt. Wenn Sie dieses Video betrachten möchten, geben Sie bitte hier die Einwilligung, dass wir Ihnen Youtube-Videos anzeigen dürfen.
Bewerten
>1x bewertet
MALAW:

news

2
17.12.13 13:30

December 17, 2013
Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in Europe for Prevention of Graft-Versus-Host Disease
European Orphan Designation Complements U.S. Orphan Designation for MultiStem Cell Therapy for Treatment of Patients with Leukemia or Related Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

CLEVELAND, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD). The Company is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell (HSC) transplant and is currently preparing for a Phase II/III clinical study in the area. The MultiStem therapy for the prevention of GvHD has also previously been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).

"We are pleased to have been granted the benefits of orphan drug designation in Europe," said Dr. Manal Morsy, Head of Global Regulatory Affairs at Athersys. "Together with our U.S. orphan designation for this indication, this EMA designation has the potential to facilitate our development of MultiStem therapy to help patients at risk of GvHD associated with HSC transplantation."  

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
>2x bewertet
CouchTrader:

..@MALAW:

 
17.12.13 14:44
oh ja .. das hebt natürlich den Kurs schon vorbörslich!

www.nasdaq.com/symbol/athx/premarket
Bewerten
>1x bewertet
>Depots
wallander:

klettert...

 
02.03.15 22:40
Bewerten
>Depots
wallander:

wieder..

 
28.07.22 16:35
Bewerten
>Depots
Vassago:

ATHX 0.12$ (-60%)

 
11.10.23 12:05
Die Stammzellenbehandlung gegen Schlaganfall erwies sich in einer Zwischenanalyse der langjährigen Ph3-Studie (in meinen Augen) als erfolglos. Nun warnt ATHX vor der Pleite.
www.fiercebiotech.com/biotech/...erapy-fails-interim-analysis
Bewerten
>Depots
Es gibt keine neuen Beiträge.
 Ich: 


Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Athersys Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  14 Athersys und Pfizer .... Chalifmann3 Vassago 11.10.23 12:05
3 13 Die Karten sind neu gemischt AnonymusNo1 Nobsy11 17.06.22 17:57
  10 --- Faktor X buran 18.03.14 06:47
2 9 und keiner hier dabei dEsiSchES Tifflor 10.02.10 14:32